ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
IO Biotech Inc

IO Biotech Inc (IOBT)

1.58
0.20
(14.49%)
Closed July 21 4:00PM
1.65
0.07
(4.43%)
After Hours: 6:21PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
1.65
Bid
1.52
Ask
2.01
Volume
1,735,250
1.35 Day's Range 1.5979
0.8163 52 Week Range 2.18
Market Cap
Previous Close
1.38
Open
1.38
Last Trade
1
@
1.6013
Last Trade Time
Financial Volume
$ 2,410,988
VWAP
1.3894
Average Volume (3m)
103,593
Shares Outstanding
65,880,914
Dividend Yield
-
PE Ratio
-1.20
Earnings Per Share (EPS)
-1.31
Revenue
-
Net Profit
-86.08M

About IO Biotech Inc

IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced imm... IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
IO Biotech Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IOBT. The last closing price for IO Biotech was $1.38. Over the last year, IO Biotech shares have traded in a share price range of $ 0.8163 to $ 2.18.

IO Biotech currently has 65,880,914 shares outstanding. The market capitalization of IO Biotech is $90.92 million. IO Biotech has a price to earnings ratio (PE ratio) of -1.20.

IOBT Latest News

IO Biotech to Present at Jefferies Global Healthcare Conference

NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its...

IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights

Outcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer...

IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its...

IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its...

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.2921.32352941181.361.59791.2512819161.34288276CS
40.4335.24590163931.221.59791.021003141.24130272CS
120.2215.38461538461.431.791.021035931.31489863CS
26-0.16-8.839779005521.811.891.021183691.50626243CS
52-0.21-11.29032258061.862.180.81631279181.49176112CS
156-14.35-89.68751617.880.8163995333.29486754CS
260-14.35-89.68751617.880.8163995333.29486754CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SERVServe Robotics Inc
$ 7.51
(185.55%)
266.26M
AUGXAugmedix Inc
$ 2.27
(147.71%)
24.14M
XCURExicure Inc
$ 0.5351
(76.02%)
14.02M
PSNLPersonalis Inc
$ 3.83
(56.33%)
22.8M
MDBHMDB Capital Holdings LLC
$ 10.675
(37.21%)
126.45k
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
124.61M
HYZNHyzon Motors Inc
$ 0.149
(-47.54%)
23.63M
MEDSTRxADE Health Inc
$ 14.92
(-33.45%)
223.27k
SILOSilo Pharma Inc
$ 2.50
(-27.95%)
11.93M
KITTNauticus Robotics Inc
$ 0.0935
(-27.46%)
28.43M
SERVServe Robotics Inc
$ 7.51
(185.55%)
266.26M
SXTP60 Degrees Pharmaceuticals Inc
$ 0.2602
(5.77%)
226.82M
NVDANVIDIA Corporation
$ 117.93
(-2.61%)
217.11M
SQQQProShares UltraPro Short QQQ
$ 8.46
(2.79%)
188.2M
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
124.61M

IOBT Discussion

View Posts
Monksdream Monksdream 15 hours ago
IOBT
πŸ‘οΈ0
stock1ace1 stock1ace1 2 days ago
Standard of care …
πŸ‘οΈ0
Monksdream Monksdream 2 weeks ago
IOBT under $2
πŸ‘οΈ0
ralfito ralfito 1 month ago
For us dummies, can you define SOC in this context? Thanks.
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 1 month ago
CEO made it pretty clear numerous times at Jefferies IMO
they will become the SOC, not only in advanced melanoma but in all stages.
They also think their platform can be used for non-cancer indications.

2 Birds in the hand and many more in the bush$$$
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 1 month ago
https://www.youtu be.com/watch?v=OvC-86SN9Ao&ab_channel=VJOncology

australian KOL on IOBT

many things pointing at it becoming the SOC one day...
πŸ‘οΈ0
axelvento axelvento 2 months ago
golden cross MA50 MA200
πŸ‘οΈ0
axelvento axelvento 2 months ago
a planned interim analysis of ORR will be conducted when the first 225 randomized patients reach one year of treatment in June 2024. The outcome of this analysis is expected in the third quarter of 2024 and, if supportive, we believe could allow for submission of a BLA for accelerated approval in the US.
Cash and cash equivalents as of March 31, 2024 were $118.0 million, compared to $143.2 million at December 31, 2023. During the three months ended March 31, 2024, the company used cash, cash equivalents and restricted cash of $24.9 million. The increase in cash use was primarily driven by milestone payments and payment of other accrued expenses associated with clinical trials, as well as the payment of year-end bonuses. The company continues to expect that it will have sufficient cash to run the company into the fourth quarter of 2025.
πŸ‘οΈ0
axelvento axelvento 3 months ago
Completed enrollment of pivotal Phase 3 trial of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), in patients with advanced melanoma; planned interim analysis for overall response rate (ORR) expected in third quarter of 2024 by independent data monitoring committee
Progressed clinical development of IO102-IO103 with first patient dosed in Phase 2 basket trial of IO102-IO103 in combination with pembrolizumab as neoadjuvant and adjuvant treatment of patients with resectable solid tumors
Ended 2023 with cash and cash equivalents of approximately $143.2 million; expected operational runway into the fourth quarter of 2025

https://www.biopharmcatalyst.com/company/IOBT/news/190095
πŸ‘οΈ0
axelvento axelvento 3 months ago
https://investors.iobiotech.com/news-events/news/news-details/2024/IO-Biotech-Announces-Abstract-Accepted-for-Presentation-at-the-2024-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting/default.aspx
πŸ‘οΈ0
axelvento axelvento 3 months ago
IO Biotech was founded in 2014 and just 10 years into the journey we are in a pivotal phase III trial I think that’s quite fast
πŸ‘οΈ0
axelvento axelvento 3 months ago
next catalyst-In November 2023, the company completed enrollment of 380 patients in its pivotal Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in advanced melanoma. The primary endpoint of the pivotal Phase 3 trial is progression free survival (PFS). The PFS analysis is event-driven and will be conducted when 226 events have occurred in the trial, which the company estimates will take place in the second half of 2025. Additionally, a planned interim analysis of overall response rate (ORR) will be conducted when the first 225 randomized patients reach one year of treatment in June 2024. The outcome of this analysis is expected in the third quarter of 2024.
πŸ‘οΈ0
Monksdream Monksdream 4 months ago
IOBT under $2
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
IOBT under $2
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
IOBT new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
IOBT new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 10 months ago
IOBT ubder $2
πŸ‘οΈ0
AJ Freely AJ Freely 11 months ago
$IOBT - 👆Up 1.8% Pre-Market/ Current Price $2.00
Announces $75 Million Private Placement Financing
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
nice
πŸ‘οΈ0
kzivann kzivann 1 year ago
Extremely heavy volume on good news. PPS down . Lower this AM. Watching

IOBT
πŸ‘οΈ0
Phosphene Phosphene 2 years ago
IO Biotech’s (NASDAQ:IOBT ) lock-up period is set to end on Wednesday, May 4th.

https://www.defenseworld.net/2022/04/27/io-biotech-inc-s-lock-up-period-set-to-end-on-may-4th-nasdaqiobt.html
πŸ‘οΈ0
conix conix 2 years ago
Bitoechs are waking up ---like they did last year.

I shopped for a number of sold out biotechs in December and picked and chose a number of sold out biotechs.

IOBT --I missed. But there are legs here. I have done well on four of my picks. Still waiting on two.

Time will tell.
πŸ‘οΈ0
Phosphene Phosphene 3 years ago
IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial

IO Biotech to initiate a Phase 2 combination trial to explore safety and efficacy for treating multiple tumor types

https://www.globenewswire.com/news-release/2021/12/06/2346557/0/en/IO-Biotech-Announces-Third-Clinical-Collaboration-with-Merck-to-Evaluate-IO102-IO103-in-Combination-With-KEYTRUDA-pembrolizumab-as-First-Line-Treatment-in-a-Phase-2-Multi-Arm-Baske.html

πŸ‘οΈ0
Eggplant Eggplant 3 years ago
What happened? IPO at $14/sh four weeks ago, and the stock has nearly folded in half. No news, and the only sellers should be the IPO buyers, right? Mystery.
πŸ‘οΈ0
Work Harder Work Harder 3 years ago
I was right on the 7

for now

Yu tell wifeie

I appreciate her time

:}
πŸ‘οΈ0
Phosphene Phosphene 3 years ago
Did Sunstone/Verland recoup initial seed?









πŸ‘οΈ0
Staypositive1 Staypositive1 3 years ago
might wait till .035...lol
πŸ‘οΈ0
Phosphene Phosphene 3 years ago
IO Biotech begins trading on Nasdaq Global Market today.

IPO pps is $14.

Thu, November 4, 2021, 11:52 PM.

https://finance.yahoo.com/news/io-biotech-inc-announces-pricing-035200314.html?fr=sycsrp_catchall

Sunstone and Novo Holdings involved.
πŸ‘οΈ0
Phosphene Phosphene 3 years ago
EXPLORATORY PROJECT TO COMPARE IO BIOTECH ANTIGENS LINKED TO MYMETICS’ (MYMX) VIROSOMES IN A PRECLINICAL TUMOR MODEL

https://www.mymetics.com/media-center/exploratory-project-compare-io-biotech-antigens-linked-mymetics-virosomes-preclinical-tumor-model/


IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial

https://www.prnewswire.com/news-releases/io-biotech-announces-clinical-collaboration-with-msd-to-evaluate-io102-io103-with-keytruda-pembrolizumab-as-first-line-treatment-in-metastatic-melanoma-patients-in-a-phase-3-trial-301375679.html
πŸ‘οΈ0
Phosphene Phosphene 3 years ago
Denmark's IO Biotech seeks $110M+ in Nasdaq debut.

https://pitchbook.com/newsletter/denmarks-io-biotech-seeks-110m-in-nasdaq-debut

https://www.fiercebiotech.com/biotech/io-biotech-raises-155m-to-trial-ido-and-pd-l1-cancer-vaccines

https://www.iobiotech.com/

The Food and Drug Administration (FDA) grants IO Biotech breakthrough therapy designation for IO102 and IO103 in combination with anti-PD-1 in unresectable/ metastatic melanoma

https://www.firstwordpharma.com/node/1783725?tsid=17
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock